Target Information

H2 Equity Partners has successfully executed its fifth investment through Fund V by making parallel investments in Healthcare 21 and Aquilant. The objective of this strategic investment is to establish a market-leading organization in healthcare and scientific sales and distribution, collaborating closely with the shareholders of Healthcare 21. The acquisition of Aquilant marks a significant step in this direction, enhancing the overall capacity and reach in the sector.

The anticipated transaction is currently awaiting approval from the Competition Authority and is expected to conclude by the end of September 2018. Upon completion, the merged entities are projected to generate revenues exceeding €150 million and employ a workforce of 450 across Ireland, the UK, Germany, and Austria.

Industry Overview

The healthcare and scientific sales and distribution industry in Europe is experiencing robust growth driven by rising healthcare expenditures, technological advancements, and an increasing demand for innovative therapies and solutions. The market is characterized by a wide array of products and services, including pharmaceuticals, medical devices, and life sciences, catering to the evolving needs of healthcare providers and patients alike.

In particular, Ireland and the UK have emerged as pivotal regions for healthcare innovation and commercial activities. The supportive regulatory environment, coupled with a highly skilled workforce, has attracted numerous international companies to establish their operations in these markets. This trend is expected to continue as organizations seek to leverage local expertise and benefit from proximity to key stakeholders in the healthcare ecosystem.

Germany and Austria also represent significant markets within Europe, characterized by their advanced healthcare systems and emphasis on quality. With rising demands for efficient healthcare services and the integration of new technologies, companies that can provide effective sales and distribution solutions will have a competitive advantage, thereby facilitating enhanced patient outcomes and operational efficiencies.

The convergence of these markets through the partnership between Aquilant and Healthcare 21 positions the combined group favorably within a dynamic landscape. The synergies created by merging the two entities will enhance their ability to respond to market demands rapidly and effectively.

Rationale Behind the Deal

The strategic rationale for this deal lies in the complementary strengths of Healthcare 21 and Aquilant, which will create a comprehensive product portfolio and innovative service offerings. Both companies have established reputations in their respective segments, and their collaboration is anticipated to broaden their market reach and enhance customer service.

Additionally, the merger is expected to enable significant cost efficiencies through integrated operations and shared resources. By unifying their strengths, the combined organization aims to enhance its competitive positioning in the market and capitalize on emerging opportunities.

Information About the Investor

H2 Equity Partners is a prominent investment firm specializing in growth capital investments in the healthcare sector. The firm has established a strong portfolio of companies, focusing on strategic partnerships that yield sustainable growth. By leveraging its industry expertise and operational know-how, H2 Equity Partners provides invaluable support to its portfolio companies in navigating complex market dynamics.

With a track record of successful investments, H2 Equity Partners is well-positioned to guide the combined entities of Aquilant and Healthcare 21 through their growth phase, driving innovation and efficiency while enhancing shareholder value.

View of Dealert

This transaction presents a promising investment opportunity for H2 Equity Partners as it consolidates its presence in the flourishing healthcare and scientific sales domain. The collaboration between Aquilant and Healthcare 21 is set to create a powerhouse that can leverage market synergies effectively, fostering growth and innovation.

Furthermore, the alignment of their offerings will enable the combined group to better serve a diverse range of customers, making it a compelling entity in the healthcare space. In a market that values efficiency and quality, the merger can lead to improved service delivery and enhanced patient outcomes.

Finally, H2 Equity Partners' expertise in steering companies towards operational excellence adds an additional layer of confidence to this investment. By focusing on leveraging shared strengths, the combined group is poised to emerge as one of Europe’s leading providers in the healthcare sector.

View Original Article